1. Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98: 946-52. DOI: 10.1161/01.CIR.98.10.946.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA. 2001;285: 2370-2375. DOI: 10.1001/ jama.285.18.2370.
3. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137: 263-72. DOI: 10.1378/chest.09-1584.
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37: 2893-2962. DOI: 10.1093/eurheartj/ehw210.
5. Hijazi Z, Oldgren J, Siegbahn A, et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34: 1475- 80. DOI: 10.1093/eurheartj/eht024 Corpus ID: 21553792.
6. Hijazi Z, Oldgren J, Siegbahn A, et al. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clinical Chemistry. 2017;63:1: 152-164. DOI:10.1373/clinchem.2016.255182.
7. Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RELY) substudy. Circulation. 2012;125: 1605-1616. DOI: 10.1161/CIRCULATIONAHA.111.038729.
8. Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;130:1847- 58. DOI: 10.1161/CIRCULATIONAHA.114.011204.
9. Миллер ОН, Бахметьева ТА, Гусева ИА и др. Причинно-следственные связи возникновения фибрилляции предсердий у больных артериальной гипертензией. Вестник аритмологии. 2006;44: 44-48.
10. Rosenberg МА, Manning WJ. Diastolic dysfuncton and risk of atrial fibrillaton: a mechanistc appraisal. Circulaton. 2012;126: 2353-2362. DOI: 10.1161/CIRCULATIONAHA.112.113233.
11. Медведева ЕА, Суркова ЕА, Лимарева ЛВ и др. Молекулярные биомаркеры в диагностике, стратификации риска и прогнозировании хронической сердечной недостаточности. Российский кардиологический журнал. 2016;8(136): 86-91. DOI: 10.15829/1560-4071-2016-8-86-91.
12. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98: 351-60. DOI: 10.1161/01. res.0000202805.73038.48.
13. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28:1- 39. DOI: 10.1016/j.echo.2014.10.003.
14. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4): 277-314. DOI: 10.1016/j.echo.2016.01.011.
15. Гизатулина ТП, Мартьянова ЛУ, Павлов АВ и др. Предикторы выраженного фиброза левого предсердия у пациентов с неклапанной фибрилляцией предсердий. Кардиология. 2020;60(2): 47-53. DOI: 10.18087/cardio.2020.2.n850.
16. Драпкина ОМ, Палаткина ЛО. Новые акценты в изучении патогенеза хронической сердечной недостаточности с сохраненной фракцией выброса: фокус на маркеры воспаления. Рациональная Фармакотерапия в Кардиологии. 2014;10(3): 317-321.
17. Unsicker K, Spittau B, Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 2013;24: 373-384. DOI: 10.1016/j.cytogfr.2013.05.003.
18. Lind L, Wallentin L, Kempf T, et al. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J. 2009;30: 2346-2353. DOI: 10.1093/eurheartj/ehp261.
19. Dostalova I, Roubicek T, Bartlova M, et al. Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low-calorie diet. Eur J Endocrinol. 2009;161:397-404. DOI: 10.1530/EJE-09-0417.
20. Tong Liu, Qingmiao Shao, Chee Yuan Ng, et al. Relation of growth differentiation factor-15 with CHA2 DS2 - VASc score in Chinese patients with non-valvular atrial fibrillation. International Journal of Cardiology. 2015; 184: 595-596. DOI: 10.1016/j.ijcard.2015.03.078.
21. Carstensen M, Herder C, Brunner EJ, et al. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur J Endocrinol. 2010;162: 913-917. DOI: 10.1530/EJE-09-1066.
22. Драпкина ОМ, Палаткина ЛО. Маркеры цитокиновой активации и оксидативного стресса у больных хронической сердечной недостаточностью. Сердечная Недостаточность. 2013;14(6): 341-6.
23. Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010;12: 1309-16. DOI: 10.1093/eurjhf/hfq151.
24. Hijazi Z, Verdecchia P, Oldgren J, et al. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial. Journal of the American Heart Association. 2019;8: e010107. DOI: 10.1161/ JAHA.118.010107.
25. Verdecchia P, Reboldi G, Di Pasquale G, et al. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014;113: 669-675. DOI: 10.1016/j.amjcard.2013.10.045.
26. Yatsuga S, Fujita Y, Ishii A, et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015;78: 814-823. DOI: 10.1002/ ana.24506.
27. Fujita Y, TaniguchiY, Shinkai S, et al. Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int. 2016;16 (1): 17-29. DOI: 10.1007/ s12035-016-0283-7.
28. Doerstlinga S, Hedberga P, Ohrvik J, et al. Growth differentiation factor 15 in a community-based sample: age-dependent reference limits and prognostic impact. Upsala Journal of Medical Sciences. 2018;123(2):86-93. DOI: 10.1080/03009734.2018.1460427.
29. Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem. 2017;63: 140-51. DOI: 10.1373/ clinchem.2016.255174.